Overview

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.

Phase:

Phase 3

Details

Lead Sponsor:

University of Arkansas

Collaborator:

Celgene Corporation

Treatments:

BB 1101
Carmustine
Cisplatin
Cyclophosphamide
Cytarabine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Etoposide
Etoposide phosphate
Interferon alpha-2
Interferon-alpha
Interferons
Liposomal doxorubicin
Melphalan
Thalidomide
Vincristine